Reporting period January – March

- **Orders received** increased by 17.2% to SEK 5,467 M (4,666)
- **Net sales** increased by 25.5% to SEK 5,153 M (4,107)
- **Profit before tax** rose by 46.0% to SEK 530 M (363)
- **Net profit** increased by 46.9% to SEK 382 M (260)
- **Earnings per share** rose by 46.8% to SEK 1.60 (1.09)
- **Acquisition of Datascope Corp. completed**
- **Continued favourable earnings outlook for the year**

First quarter 2009

Operations targeted at the healthcare market have historically shown limited sensitivity to economic fluctuations. Due to the intensity of the prevailing recession, particularly in terms of the US market, Getinge is lowering its growth ambitions for the year. Despite the challenges, we expect continued favourable growth for the year of about 15% before taxes.

Orders received

During the period, orders received declined organically for the Group by 5.5%, which should be viewed in relation to the very high level of orders received during the year-earlier period, when orders received rose by 10.6%. Orders received during the quarter were in line with the revised growth targets communicated by the Group for the current year, entailing that the Group expects organic sales growth of 2 to 3%.

Orders received during the period were organically lower for all business areas. In the US market, the volume trend for medical technical capital goods was particularly weak, while growth pertaining to consumable goods and services, which are a growing part of the Group's operations, advanced according to plan. The decline in orders received in Europe and Latin America during the period is assessed as transitory, and the Group forecasts a rising trend in orders received in these regions during the coming quarter.

Results

Consolidated profit before tax amounted to SEK 530 million (363), up 46%. The profit includes a currency hedge gain of SEK 228 million which arose in conjunction with the new issue of shares that partially financed the acquisition of Datascope. The quarterly profit was further impacted by restructuring costs totalling SEK 37 million (23) attributable to Extended Care and Medical Systems. The Group's EBITA excluding restructuring costs amounted to SEK 652 million, which was in line with the year-earlier period. The lower growth in the Group's EBITA was primarily attributable to organic sales growing by only a moderate 0.7% after a strong fourth quarter in 2008. Datascope, which was consolidated into the Group as of February of the current year, performed well.

Operating cash flow excluding restructuring costs increased by 12% to SEK 1,040 million (928).

Outlook

Demand for the Group's products weakened during the period. The decline was particularly noticeable for medical technical capital goods in the US market and for orders to the pharmaceutical industry in general. The Group also expects demand in certain emerging markets, including Russia, to weaken during the current year. For other geographical regions, the Group expects a limited slowdown in demand. Services and consumable goods are a growing part of the Group's sales, and the impact of the weakened demand was significantly lower on this segment.

Overall, organic sales growth for the current year is expected to rise by 2 to 3%. Datascope, which is not included in the calculation of organic growth, is expected to grow more rapidly.

Despite the weakened demand, Getinge expects to continue to be able to maintain favourable profit growth. Profit before tax, calculated on the prevailing currency situation, is expected to rise by approximately 15%, including restructuring costs of about SEK 200 million for the Datascope acquisition. Excluding integration costs related to the Datascope acquisition, profit before tax is expected to increase by about 25%.

Business area Medical Systems

Orders received

Orders received per market	**2009 3 Mon**	2008 3 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**1 053**	807	*2.7%*
USA and Canada	**864**	619	*-10.1%*
Asia and Australia	**486**	265	*16.5%*
Rest of the world	**196**	218	*-21.2%*
Business area total	**2 599**	1 909	*-2.3%*

During the period, orders received by Medical Systems declined by 2.3% compared with the strong first quarter of the preceding year. In the European market, orders received increased by slightly less than 3%, with favourable growth in Southern and Eastern Europe. In Northern Europe, growth was weaker, while the remaining markets were in line with the year-earlier period.

In the US, orders received declined noticeably for medical technical capital goods, particularly for Critical Care's products. Surgical Workplaces also reported a decrease in volume, but was impacted to a lesser extent because most of its products are included in project deliveries for hospital renovation and construction projects, where the investment decisions are taken long before orders are placed. Datascope, which is not included in the calculation of organic growth, had a very strong performance during the period.

In emerging markets, the outcome was mixed. The Middle East and large portions of the Asian markets had very favourable performances, while Latin America, which began 2008 with a very strong performance, was weaker.

Results

	2009 3 Mon	2008 3 Mon	*Change*	2008 FY
Net sales, SEK million	**2 453**	1 786	*37.3%*	8 416
adjusted for currency flucs.& corp.acqs			*-2.3%*	
Gross profit	**1 385**	1 023	*35.4%*	4 723
Gross margin %	***56.5%***	*57.3%*	*-0.8%*	*56.1%*
Operating cost, SEK million	**-1 137**	-740	*53.6%*	-3 140
EBITA before restructuring and integration costs	**346**	331	*4.5%*	1 784
EBITA margin %	***14.1%***	*18.5%*	*-4.4%*	21.2%
Restructuring and integration costs	**-11**	-3		-72
EBIT	**237**	280	*-15.4%*	1 511
EBIT margin %	***9.7%***	*15.7%*	*-6.0%*	*18.0%*

Medical Systems' EBITA excluding restructuring costs increased modestly by 4.5% to SEK 346 million (331). During the quarter, the business area was charged with restructuring costs of SEK 11 million (3) in conjunction with the Datascope acquisition. The weak profit growth and lower profit margin during the quarter were due to a declining trend in sales growth during the period, with an organic decrease of 2.3%. During the year-earlier period, the earnings trend was very favourable, especially for Critical Care and Cardiovascular, which were positively impacted by various non-recurring effects. Datascope, which was included in the business area's results as of February of the current year, performed very well.

Activities

Integration of cardiac and vascular surgery divisions

The work of integrating the divisions acquired from Boston Scientific at the beginning of 2008 continued according to plan.

The coordination of the sales organisations that were historically part of the Boston Scientific organisation is now complete, and they are now integrated into Medical Systems' global marketing organisation. Actions to develop and realise possible sales synergies that will contribute to the ability to maintain organic growth of 10% are proceeding favourably. Sales of Perfusion products to customers in the US began, and several customers placed orders. Above all, sales of Endoscopic Vessel Harvesting (EVH) products outside the US have been intensified, with favourable results in certain markets in Europe.

The annual cost synergies of SEK 120 million that were announced in conjunction with the acquisition will also be realised according to plan. Most of the cost savings relate to the relocation of cardiac surgery production from Puerto Rico to the existing factory in Wayne in the US. Production has already begun on a minor scale in Wayne, and the move is expected to be completed by the end of the current year.

Integration of Datascope

The integration of Datascope, which was consolidated in Medical Systems and consolidated earnings as of February of the current year, has proceeded very favourably.

Complementarities in terms of products and geographical markets will ensure organic growth of 10%.

Cost synergies are expected to total approximately SEK 170 million annually as of 2010. They will be realised by coordinating the sales companies of Datascope and Medical Systems in about ten markets and through cost savings in conjunction with the delisting of Datascope and the closure of its headquarters.

Since the takeover, Datascope's volume development has exceeded expectations.

Product development and launches

In June of the current year, Medical Systems plans to implement the official launch of its new anaesthesia programme at the ESA conference in Milan, Italy. The commercial rollout of FLOW-i will occur in a limited number of markets toward the end of the current year to safeguard positive customer reception before broader commercialisation begins in 2010.

The introduction of Cardiohelp, the business area's product for cardiovascular support, is developing very favourably. The product continues to attract substantial attention in the press and, as previously announced, deliveries are planned for the middle of the current year.

During the quarter, the first implants of Cardiovascular's Fusion Graft were performed on patients in Germany. Fusion is a reinforced vascular implant made of Teflon with an outer textile casing. Planned applications for the product include bypass operations in which the patient's own vessels are not in sufficient condition to be used and in which a stent intervention is not a treatment option.

Business area Extended Care

Orders received

Orders received per market	2009 3 Mon	2008 3 Mon	Change adjusted for curr.flucs.&corp.acqs.
Europe	**990**	1 063	*-12.2%*
USA and Canada	**479**	409	*-7.2%*
Asia and Australia	**138**	148	*-8.6%*
Rest of the world	**37**	23	*65.2%*
Business area total	**1 644**	1 643	*-9.5%*

Extended Care's orders received declined by 9.5% during the period. As was the case with other business areas, Extended Care reported a strong improvement in orders received during the year-earlier period.

The decrease in the European market was entirely attributable to a decline in orders received in the UK for Huntleigh's products. Toward the end of 2007 and in early 2008, Huntleigh in the UK experienced a very strong increase in orders received, primarily pertaining to hospital beds, which entails that it is particularly challenging to compare figures. The business area expects favourable growth in the UK during the coming quarter. In other European markets, volumes were in line with or higher than in the year-earlier period.

In the US market, orders received decreased, primarily in relation to patient handling products. For other product areas, growth was stable in the US.

Results

	2009 3 Mon	2008 3 Mon	Change	2008 FY
Net sales, SEK million	**1 649**	1 398	*18.0%*	6 174
adjusted for currency flucs.& corp.acqs			*6.7%*	
Gross profit	**755**	693	*8.9%*	2 847
Gross margin %	***45.8%***	*49.6%*	*-3.8%*	*46.1%*
Operating cost, SEK million	**-553**	-486	*13.8%*	-1 969
EBITA before restructuring and integration costs	**231**	235	*-1.7%*	992
EBITA margin %	***14.0%***	*16.8%*	*-2.8%*	*16.1%*
Restructuring and integration costs	**-26**	-19		-145
EBIT	**176**	188	*-6.4%*	733
EBIT margin %	***10.7%***	*13.4%*	*-2.7%*	*11.9%*

Extended Care's EBITA for the period was in line with the year-earlier period and amounted to SEK 231 million (235). Restructuring costs of SEK 26 million (19) related to the merger of the US marketing companies of Extended Care and Huntleigh were charged against the period. Sales increased organically by 6.7% during the period, and costs rose moderately in constant currency. The gross margin for the period was below that of the year-earlier period but in line with the outcome for 2008. Efforts to normalise the business area's logistics costs are proceeding in the right direction and are expected to lead to a more favourable cost situation during the second half of the current year.

Activities

Merger of Extended Care's two sales companies in the US

During the period, the business area implemented a previously announced merger of the US sales companies of Huntleigh and Extended Care to reduce costs and increase competitiveness. Considering the weakened demand for capital goods in the US, the savings programme has been increased in relation to what was previously announced. Annual savings for the now-implemented activities amount to approximately USD 7 million compared with the previously announced USD 3 million. Structural costs for the activities are expected to total about USD 4 million.

Efficiency enhancements of logistics and transportation functions

Due to the problems and increasing costs experienced by Extended Care in the wake of the outsourcing of the business area's transportation and logistics function in 2008, comprehensive efforts have been initiated to reverse the cost trend. The business area expects to be able to normalise transport costs through improved procurement and better coordination as of the middle of the current year. Extended Care also expects to gradually be able to lower logistics costs as the product range and stock levels are reduced.

Business area Infection Control

Orders received

Orders received per market	**2009 3 Mon**	2008 3 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**665**	606	*0.8%*
USA and Canada	**381**	324	*-10.5%*
Asia and Australia	**159**	131	*5.0%*
Rest of the world	**19**	53	*-66.2%*
Business area total	**1 224**	1 114	*-5.2%*

Infection Control's orders received declined organically by 5.2% during the quarter.

In the European market, orders received were in line with the year-earlier period. In German-speaking markets, orders received reported a declining trend, while other European markets were in line with or somewhat higher than the year-earlier period.

In the US, orders received decreased. As was the case with the trend for the fourth quarter of 2008, the decline was primarily attributable to weak demand from customers in the pharmaceutical industry. For demand from hospital customers, the decline was more limited.

In emerging markets, orders received were mixed, with favourable growth in China, Southeast Asia and the Middle East, while the trend in Latin America was weak compared with the strong year-earlier period.

Results

	2009 3 Mon	2008 3 Mon	*Change*	2008 FY
Net sales, SEK million	**1 051**	924	*13.7%*	4 682
adjusted for currency flucs.& corp.acqs			*-2.5%*	
Gross profit	**391**	352	*11.1%*	1 763
Gross margin %	***37.2%***	*38.1%*	*-0.9%*	*37.7%*
Operating cost, SEK million	**-321**	-273	*17.6%*	-1 126
EBITA before restructuring and integration costs	**74**	83	*-10.8%*	652
EBITA margin %	***7.0%***	*9.0%*	*-2.0%*	*13.9%*
Restructuring and integration costs	**–**	-1		-3
EBIT	**70**	78	*-10.3%*	634
EBIT margin %	***6.7%***	*8.4%*	*-1.7%*	*13.5%*

EBITA for the period declined somewhat and amounted to SEK 74 million (83). Organic sales volume decreased by 2.5% and was the primary reason for the decline in profit. Costs and gross margin were comparable with the year-earlier period measured in constant currency.

Activities

Product launches

ED-flow, the business area's disinfector for flexible endoscopes, was launched at the Medica trade fair at the end of 2008. Orders have begun to be placed by customers at sterile centres and endoscopy centres. ED-flow has double chambers that can be loaded independently of each other, resulting in a significantly faster process time than equivalent products that have only one chamber.

New marketing company in India

During the quarter, the business area opened a marketing company in Mumbai, India, to capitalise on growth opportunities in this expansive region. Getinge has been active in the Indian market for a long period.

Acquisitions

In the first quarter of 2009, the business area acquired Numac Validation Services, a company that offers service and maintenance for disinfection equipment. The company, which is situated in the UK, has 11 employees and annual sales of SEK 14 million.

Other information

Irregularities in Huntleigh's French subsidiary

Getinge has decided to initiate a legal investigation into whether Deloitte France S.A., in its capacity as auditor of Huntleigh's French subsidiary, failed in its obligations as an auditor when it did not detect the irregularities in HNE Medical SAS' accounting from 2000 to 2008 that have now been detected. In a French court, Getinge has requested that an independent expert be appointed to make a statement regarding Deloitte's responsibility as an auditor.

The extent of the irregularities entails that HNE Medical's combined profit for the period 2000-2008 has been overestimated by approximately SEK 215 million, of which net profit for 2007 and 2008 was overestimated by SEK 27 million and SEK 29 million, respectively. Due to the prevailing circumstances, Getinge has revised the profits for 2007 and 2008 with the amounts specified here. The remaining amount of approximately SEK 159 million has entailed an adjustment of the goodwill item that arose as a consequence of the acquisition of Huntleigh Technology PLC. Correction of the profit for 2008 is allocated in accordance with the following:

SEK million	2008 Q1	2008 Q2	2008 Q3	2008 Q4	2008
Net Profit	-6	-7	-5	-11	-29

Accounting

This interim report was prepared for the Group in accordance with the Annual Accounts Act and IAS 34 Interim Financial Reporting and for the Parent Company, in accordance with the Annual Accounts Act. As of 2009, Getinge applies IFRS 8, Operating Segments, for the recognition of operating sectors. The impact of the application has not affected the number of sectors presented by Getinge or their presentation. As of 1 January 2009, Getinge also applies IAS 1, Amendment, Presentation of Financial Statements, which entails that a comprehensive earnings statement be presented. The statement is included on page 14 of this report. The application of the IAS 1 Amendment has had no impact on valuation principles. Otherwise, the accounting principles and methods of calculation used in this interim report are identical to those used in the most recent Annual Report. This report has not been subject to an auditor's review.

Risk management

Political decisions altering the healthcare reimbursement system represent the single greatest risk to the Getinge Group. The risk to the Group as a whole is limited by the fact that Getinge is active in a large number of countries. The Group's operational risks are limited, since as a rule, its customers' operations are funded directly or indirectly from public funds. The Group's Risk Management team works continuously to minimise the risk of production disruptions.
Financial risk management. Getinge is exposed to a number of financial risks in its operations. "Financial risks" refer primarily to risks related to currency and interest rates as well as credit risks. Risk management is regulated by a financial policy established by the Board of Directors. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with Group management and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks, and credit and counterparty risks.

Forward-looking information

This report contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding the economy, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (second quarter 2009) will be published on 13 July 2009.

Teleconference

A teleconference will be held today at 2:00 p.m. Swedish time.

To participate, please call:

Sweden: + 46 (0)8 506 269 04
UK: + 44 (0)207 108 6205

1:45 p.m. Call the conference phone number
2:00 p.m. Review of the interim report
2:20 p.m. Question-and-answer period
3:00 p.m. Conclusion

A recorded version of the teleconference will be available for five working days at the following telephone number:
Sweden: +46 (0)8 506 269 49, access code 229888#

During the teleconference, a presentation will be held. For access to the presentation, please click on the following link:

https://www.anywhereconference.com/?Conference=108229888&PIN=334536

The Board of Directors and President ensure that the interim report provides a true and fair overview of the Parent Company and the Group's operations, position and earnings and describes the material risks faced by the Parent Company and the Group.

Getinge, 21 April 2009

Carl Bennet *Chairman*	Johan Bygge	Rolf Ekedahl
Jan Forslund	Carola Lemne	Margareta Norell Bergendahl
Bo Sehlin	Johan Stern	Johan Malmquist *President and CEO*

Getinge AB
Box 69, 310 44 Getinge
Telephone 035-15 55 00. Telefax 035-549 52
e-mail info@getinge.com
Corporate Registration Number 556408-5032
www.getingegroup.com

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.

Consolidated Income statement

SEK million	2009 3 Mon	2008 3 Mon	Change	2008 FY
Net sales	**5 153**	4 107	*25.5%*	19 272
Cost of goods sold	**-2 622**	-2 040	*28.5%*	-9 939
Gross profit	**2 531**	2 067	*22.4%*	9 333
Gross margin	*49.1%*	*50.3%*	*-1.2%*	*48.4%*
Selling expenses	**-1 257**	-913	*37.7%*	-3 894
Administrative expenses	**-587**	-437	*34.3%*	-1 822
Research & development costs [1]	**-160**	-145	*10.3%*	-497
Restructuring and integration costs	**-37**	-23	*60.9%*	-221
Other operating income and expenses	**-6**	-4	*50.0%*	-22
Operating profit [2]	**484**	545	*-11.2%*	2 877
Operating margin	*9.4%*	*13.3%*	*-3.9%*	*14.9%*
Financial Net, SEK [3]	**46**	-182		-751
Profit before tax	**530**	363	*46.0%*	2 126
Taxes	**-148**	-103		-603
Net profit	**382**	260	*46.9%*	1 523
Attributable to:				
Parent company's shareholders	**382**	260		1 524
Minority interest	**0**	0		-1
Net profit	**382**	260		1 523
Earnings per share, SEK [4]	**1.60**	1.09	*46.8%*	7.23

1 Development costs totalling SEK 123 (85) million have been capitalised during the quarter.

2 Operating profit is charged with

— amort. Intangibles on acquired companies	***-131***	*-81*	*-330*
— amort. intangibles	***-42***	*-27*	*-116*
— depr. on other fixed assets	***-172***	*-119*	*-523*
	-345	*-227*	*-969*

3 Financial net income

— currency gains	***228***
— net of interest incomes, interest expenses and other financial expenses	***-182***
	46

4 There are no dilutions

Comprehensive earnings statement

SEK million	**2009 3 Mon**	2008 3 Mon
Profit for the period	**382**	260
Other comprehensive earnings		
Translation differences	**499**	-531
Cash-flow hedges	**-288**	7
Income tax related to other partial result items	**76**	-1
Other comprehensive earnings for the period, net after tax	**287**	-525
Total comprehensive earnings for the period	**669**	-265
Comprehensive earnings attributable to:		
Parent Company shareholders	**669**	-265
Minority interest	**-**	-

Quarterly results

SEK million	2007 Q 1	2007 Q 2	2007 Q 3	2007 Q 4	2008 Q 1	2008 Q 2	2008 Q 3	2008 Q 4	2009 Q 1
Net sales	3 415	4 029	3 845	5 156	4 107	4 452	4 290	6 423	5 153
Cost of goods sold	-1 751	-2 206	-2 141	-2 827	-2 040	-2 244	-2 267	-3 388	-2 622
Gross profit	1 664	1 823	1 704	2 329	2 067	2 208	2 023	3 035	2 531
Operating cost	-1 264	-1 327	-1 351	-1 323	-1 522	-1 641	-1 499	-1 794	-2 047
Operating profit	400	496	353	1 006	545	567	524	1 241	484
Financial net	-114	-130	-132	-131	-182	-175	-190	-204	46.0
Profit before tax	286	366	221	875	363	392	334	1 037	530
Taxes	-83	-106	-63	-263	-103	-109	-92	-299	-148
Profit after tax	203	260	158	612	260	283	242	738	382

Consolidated Balance sheet

Assets SEK million	**2009 31 Mar**	2008 31 Mar	2008 31 Dec
Intangible fixed assets	**21 596**	14 032	15 879
Tangible fixed assets	**3 912**	2 605	3 257
Financial assets	**1 240**	979	1 250
Stock-in-trade	**4 795**	3 271	4 015
Current receivables	**7 194**	5 263	7 125
Cash and cash equivalents	**1 676**	1 610	1 506
Total assets	**40 413**	27 760	33 032

Shareholders' equity & Liabilities			
Shareholders' equity	**11 345**	7 820	10 676
Long-term liabilities	**22 250**	14 934	15 847
Current liabilities	**6 818**	5 006	6 509
Total Equity & Liabilities	**40 413**	27 760	33 032

Consolidated Cash flow statement

SEK million	**2009 3 Mon**	2008 3 Mon	2008 FY
Current activities			
Operating profit	**484**	545	2 877
Adjustment for items not included in cash flow	**371**	171	939
Financial items	**46**	-182	-751
Taxes paid	**-150**	-204	-618
Cash flow before changes in working capital	**751**	330	2 447
Changes in working capital			
Stock-in-trade	**-392**	-326	-575
Rental equipment	**-67**	-34	-228
Current receivables	**978**	437	-360
Current operating liabilities	**-348**	97	191
Cash flow from operations	**922**	504	1 475
Investments			
Acquisition of subsidiaries	**-5 050**	-4 894	-5 008
Other acqusition expenses	**-391**	–	
Investments in intangible fixed assets	**-136**	-90	-476
Investments in tangible fixed assets	**-288**	-120	-617
Disposal of tangible fixed assets	**3**	-	22
Cash flow from investments	**-5 862**	-5 104	-6 079
Financial activities			
Change in interest-bearing debt	**6 056**	3 182	3 524
Change in long-term receivables	**-156**	59	-414
New share issue	**–**	1 492	3 453
Dividend paid	**–**	–	-515
Cash flow from financial activities	**5 900**	4 733	6 048
Cash flow for the period	**960**	133	1 444
Cash and cash equivalents at begin of the year	**1 506**	894	894
Translation differences	**-790**	583	-832
Cash and cash equivalents at end of the period	**1 676**	1 610	1 506

Operating cash flow statement

SEK million	**2009 3 Mon**	2008 3 Mon	2008 FY
Business activities			
Operating profit	**484**	545	2 877
Restructuring costs	**37**	23	221
Adjustment for items not included in cash flow	**348**	186	941
	869	754	4 039
Changes in operating capital			
Stock-in-trade	**-392**	-326	-575
Rental equipment	**-67**	-34	-228
Current receivables	**978**	437	-360
Current liabilities	**-348**	97	191
Operating cash flow	**1 040**	928	3 067
Restructuring cost cash generated	**-14**	-38	-223
Operating cash flow after restructuring cost	**1 026**	890	2 844

Consolidated Net interest-bearing debt

SEK million	**2009 31 Mar**	2008 31 Mar	2008 31 Dec
Debt to credit institutions	**19 279**	12 689	13 244
Provisions for pensions, interest-bearing	**1 763**	1 750	1 730
Less liquid funds	**-1 676**	-1 610	-1 506
Net interest-bearing debt	**19 366**	12 829	13 468

Changes to shareholders' equity

SEK million	Share capital	Other contributed capital	Reserves	Profit brought forward	Total	Minority interests	Total equity
Opening balance on 1 January 2008	101	2 525	-194	4 136	**6 568**	25	**6 593**
Total comprehensive earnings for the period			-525	260	**-265**		**-265**
New share issue		1 492			**1 492**		**1 492**
Closing balance on 31 March 2008	**101**	**4 017**	**-719**	**4 396**	**7 795**	**25**	**7 820**
Opening balance on 1 January 2009	107	5 972	-572	5 145	**10 652**	24	**10 676**
Total comprehensive earnings for the period			287	382	**669**		**669**
Closing balance on 31 March 2009	**107**	**5 972**	**-285**	**5 527**	**11 321**	**24**	**11 345**

Key figures

	2009 3 Mon	2008 3 Mon	Change	2007 3 mån	2008 FY
Orders received, SEK million	**5 467**	4 666	*17.2%*	3 737	19 447
adjusted for currency flucs.& corp.acqs			*-5.5%*		
Net sales, SEK million	**5 153**	4 107	*25.5%*	3 415	19 272
adjusted for currency flucs.& corp.acqs			*0.7%*		
EBITA before restructuring- and integration costs	**652**	649	*0.5%*	479	3 427
EBITA margin before restructuring- and integration costs	**12.7%**	15.8%	*-3.1%*	14.0%	17.8%
Restructuring and integration costs	**37**	23		51	220
EBITA	**615**	626	*-1.8%*	428	3 207
EBITA margin	**11.9%**	15.2%	*-3.3%*	12.5%	16.6%
Earnings per share after full tax, SEK	**1.60**	1.09	*46.8%*	1.01	7.23
Number of shares, thousands	**238 323**	201 874	*18.1%*	201 874	214 491
Operating capital, SEK million	**23 277**	16 542	*40.7%*	10 223	22 051
Return on operating capital, per cent	**12.7%**	15.4%	*-2.7%*	19.3%	14.0%
Return on equity, per cent	**19.9%**	20.1%	*-0.2%*	22.1%	29.0%
Net debt/equity ratio, multiple	**1.71**	1.64	*0.07*	1.61	1.26
Interest cover, multiple	**4.2**	4.1	*0.1*	7.2	4.0
Equity/assets ratio, per cent	**28.1%**	28.2%	*-0.1%*	28.2%	32.3%
Equity per share, SEK	**47.50**	38.77	*22.5%*	30.92	44.70
Number of employees at the period's end	**12 401**	11 090	*11.8%*	10 343	11 623

Five-year review

SEK million	2009 31 Mar	2008 31 Mar	2007 31 Mar	2006 31 Mar	2005 31 Mar
Net Sales	5 153	4 107	3 415	2 975	2 525
Profit before tax	382	260	203	191	225
Earnings per share	1.60	1.09	1.00	0.93	1.09
Return of equity	19.9%	20.1%	22.1%	22.3%	28.4%
Operating margin	9.4%	13.3%	11.7%	10.4%	14.4%

Income statement for the parent company

Mkr	2009 3 Mon	2008 3 Mon	2008 Helår
Administrative expenses	**-29**	-25	-88
Operating profit	**-29**	-25	-88
Financial net	**-127**	203	-1 848
Profit after financial items	**-156**	178	-1 936
Appropriations	**–**	–	–
Profit before tax	**-156**	178	-1 936
Taxes	**39**	-50	591
Net profit	**-117**	128	-1 345

Balance sheet for the parent company

Assets SEK million	2009 31 Mar	2008 31 Mar	2008 31 Dec
Tangible fixed assets	**33**	11	12
Shares in group companies	**4 796**	4 767	4 796
Long-term financial receivables	**19**	40	19
Deferred tax asset	**27**	86	27
Receivable from group companies	**25 933**	16 077	19 770
Short-term receivables	**129**	580	575
Total assets	**30 937**	21 561	25 199
Shareholders' equity & Liabilities			
Shareholders' equity	**6 942**	5 449	7 101
Long-term liabilities	**17 875**	11 508	12 269
Current liabilities	**6 120**	4 604	5 829
Total Equity & Liabilities	**30 937**	21 561	25 199

Information pertaining to the Parent Company’s performance during the reporting period January-March 2009

Income statement At the end of the period, claims and liabilities in foreign currencies were measured at the closing date exchange rate, and an unrealised loss of SEK 55 million was included in net financial income for the quarter.

Balance sheet During the first quarter of 2009, Datascope Inc. was acquired for a purchase consideration of USD 617 million (SEK 5,050 million). The increase in the Parent Company’s long-term liabilities was primarily attributable to the financing of the acquisition.

Companies acquired in 2009

Datascope

In January 2009, Getinge acquired the US company Datascope, which operates in the area of cardiac support and vascular interventions. The acquisition price totalled approximately USD 617 million (SEK 5,050 million). The acquisition was recognised according to the purchase method. Acquisition costs in conjunction with the acqusition amounted to approximately SEK 60 million.

Acquired net assets and goodwill in conjunction with the acquisition

SEK M	Net assets	Balance sheet at the time of acquisition	Adjustment to fair value	Fair value
	Intangible assets	155	1 807	1 962
	Tangible assets	357		357
	Other fixed assets	415		415
	Inventories	288		288
	Other current assets	872		872
	Cash and cash equivalents	2 070		2 070
	Provisions	-253	-614	-867
	Current liabilities	-1 044		-1 044
		2 860	1 193	4 053
	Goodwill			3 067
	Total acquisitions with cash and cash equivalents			**7 120**

Net outflow of cash and cash equivalents due to the acquisition

Paid cash and cash equivalents for the acquisition	7 120
Cash and cash equivalents in the acquired company at the time of acquisition	-2 070
	5 050

Goodwill that arose in conjunction with the transaction is attributable to future integration synergies within the areas of customer potential, geographical coverage, production, sales and distribution.

The company is included in Getinge's sales and operating profit as of 1 February 2009.

It is not practicable to specify the capital gain for the acquisition since the time of acquisition because an extensive integration was carried out during the quarter.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortisation of intangible assets identified in conjunction with corporate acquisitions.
BRIC	Brazil, Russia, India, China